Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9635042 | 0.90 | CES2 (0.43) | CES2CES1MEN1KMT2ATHRB | |
| SCHEMBL8528421 | 0.90 | CES2 (0.46) | CES2CES1MEN1KMT2ATHRB | |
| SCHEMBL29150329 | 0.77 | CES2 (0.42) | CES2CES1MEN1KMT2ATHRB | |
| SCHEMBL29042640 | 0.74 | CYP3A4 (0.39) | CES2CES1MEN1KMT2ATHRB | |
| SCHEMBL31727216 | 0.72 | THRB (0.37) | CES2CES1MEN1KMT2ATHRB | |
| SCHEMBL19360080 | 0.71 | CES2 (0.42) | CES2CES1MEN1KMT2ATHRB | |
| SCHEMBL823811 | 0.71 | CES2 (0.42) | CES2CES1MEN1KMT2ATHRB | |
| SCHEMBL124392 | 0.71 | CES2 (0.42) | CES2CES1MEN1KMT2ATHRB | |
| SCHEMBL10406919 | 0.70 | CES2 (0.42) | CES2CES1HTTSMN1; SMN2 | |
| SCHEMBL9633943 | 0.70 | CYP3A4 (0.39) | MEN1KMT2ATHRBCYP3A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1319656-B1 | A NEW PROCESS FOR PREPARING A QUINOLONE-CARBOXYLIC ACID | LYNCHEM CO LTD (CN) | 2006-08-23 | — | — | EP | disclosed |
| US-6699992-B2 | REACTING M-FLUOROACETOPHENONE COMPOUND WITH ALKYL CARBONATE; REACTING ESTER OBTAINED WITH ALKYL ORTHOFORMATE AND AMINE; CYCLIZATION IN BASE | LYNCHEM CO., LTD. (CN) | 2004-03-02 | — | — | US | disclosed |
| US-20030166936-A1 | Process for preparing a quinolone-carboxylic acid | LYNCHEM CO., LTD. (CN) | 2003-09-04 | — | — | US | disclosed |
| EP-1319656-A1 | A NEW PROCESS FOR PREPARING A QUINOLONE-CARBOXYLIC ACID | Lynchem Co., Ltd. (CN) | 2003-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166936-A1 | Process for preparing a quinolone-carboxylic acid | CYP4B1, QPCT, NQO2 | CES2 1150/4885CES1 313/4885MEN1 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.